2022-501811-14-00RecruitingPhase 1/2
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Sept 2026
Brief summary (registry, in English)
To evaluate the proportion of false negative (FN) PET results for [68Ga]Ga-PentixaFor PET/AC-CT at baseline.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 24 Mar 2023
- Start date
- 20 Sept 2024
- Lead sponsor
- University Of Antwerp
- Diseases
- Multiple myeloma
- EU CT number
- 2022-501811-14-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 90
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed multiple myeloma who are planned for induction chemotherapy followed by a stem-cell transplant (ASCT). It tests a [68Ga]Ga-PentixaFor PET scan.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed multiple myeloma by current IMWG criteria, scheduled for induction chemotherapy followed by ASCT. WHO performance status 0-2; above 2 may be allowed if fit for intensive chemotherapy in the physician's opinion. Life expectancy over 12 months.
- Earlier treatment
- No induction chemotherapy yet: the [68Ga]Ga-PentixaFor PET/CT must be scheduled before it starts.
- Biomarker or test result
- A baseline 18F-FDG PET/CT scan is needed. The [68Ga]Ga-PentixaFor scan must come at most 14 days from the 18F-FDG scan.
Main reasons for not taking part
- A condition that may affect following the study, such as severe claustrophobia or not being able to lie still for 30 minutes
- Another cancer, except non-melanoma skin cancer, carcinoma in situ of the cervix, or a cancer treated and in remission for more than 5 years
- Pregnant or breastfeeding
- Refusal or inability to give written informed consent
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of concomitant presence of any other malignancy, except for: non-melanoma skin cancer, carcinoma in situ of the cervix, or any other effectively treated malignancy that has been in remission for >5 years or that is highly likely to be cured at the time of enrollment.
Other illness
- Any physical or physiological condition that may affect adherence to the study protocol, e.g severe claustrophobia or the inability to lie still for 30 minutes.
Other
- Pregnant or breastfeeding
- Refusal or inability to provide written informed consent
Who the study is looking for
- Transplant-eligible newly diagnosed multiple myeloma based on current IMWG criteria and scheduled for induction chemotherapy followed by ASCT.
- Baseline 18F-FDG PET/CT scan
- WHO performance status 0-2 (WHO > 2 can be allowed if the patient is fit for intensive chemotherapy based on the opinion of the physician).
- 18 years of older.
- Signed informed consent.
- Life expectancy > 12 months, based on clinical judgement.
- Baseline [68Ga]Ga-PentixaFor PET/CT should be scheduled before starting induction chemotherapy.
- An interval of maximum 14 days is allowed between the 18F-FDG and [68Ga]Ga-PentixaFor PET/CT scans (Specific for this study).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Antwerp University Hospital | Edegem | Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Gent | Belgium | Recruiting |
| UZ Leuven | Leuven | Belgium | Recruiting |
| Amsterdam UMC | Amsterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.